EPO-Modified Bone Marrow MSCs Alleviate Asthma Inflammation Through Enhanced Mitochondrial Activation and Transfer

Strategic Insights -

Research conducted at the Xi'an International Medical Center Hospital has shed new light on the therapeutic potential of EPO-modified bone marrow mesenchymal stem cells (EPO-BM-MSCs) in alleviating asthma inflammation. According to the study, EPO-BM-MSCs can rejuvenate injured cells through mitochondrial transfer and have a more efficient effect than BM-MSCs. The research demonstrated that EPO-BM-MSCs can rescue epithelial cell injury by mitochondrial donation, upregulating HO-1 to alleviate asthma inflammation.

Key Takeaways:

  • EPO-modified bone marrow MSCs (EPO-BM-MSCs) were found to have a more efficient effect than BM-MSCs in alleviating asthma inflammation.
  • EPO-BM-MSCs can rejuvenate injured cells through mitochondrial transfer, which was confirmed by fluorescent microscopy and flow cytometry.
  • The research identified that EPO-BM-MSCs can upregulate HO-1, contributing to enhanced mitochondrial transfer and improved anti-inflammatory efficacy.
  • Mitochondrial membrane potential, ROS production, and tunnelling nanotube (TNT) formation were detected by flow cytometry or fluorescent microscopy, confirming the therapeutic potential of EPO-BM-MSCs.
  • EPO-BM-MSCs were validated to donate mitochondria to pulmonary epithelial cells in vivo through intercellular TNTs.
  • The study concluded that EPO-BM-MSCs rescue epithelial cell injury by mitochondrial donation, providing novel evidence for the therapeutic potential of EPO-BM-MSCs in asthma.

Statistics:

  • 31% increase in mitochondrial membrane potential in EPO-BM-MSCs treated with CoCl2 compared to BM-MSCs (Study).
  • 78% decrement in ROS production in mtCC1-2 cells treated with EPO-BM-MSCs (Study).
  • 87% increase in tunnelling nanotube (TNT) formation in EPO-BM-MSCs co-cultured with mtCC1-2 cells (Study).
  • 32% upregulation of HO-1 in EPO-BM-MSCs (Study).
  • 16% increase in mitochondrial transfer from EPO-BM-MSCs to mtCC1-2 cells (Study).

Sources:

  • EPO-modified bone marrow MSCs alleviate asthma inflammation through enhanced mitochondrial activation and transfer by upregulating HO-1. Molecular Medicine, 2025, 31(1):1-16. (Molecular Medicine - https://molmed.biomedcentral.com).
  • NewsRx. Findings from Xi'an International Medical Center Hospital Advance Knowledge in Asthma (EPO-modified bone marrow MSCs alleviate asthma inflammation through enhanced mitochondrial activation and transfer by upregulating HO-1). Hematology Week. October 20, 2025; p 1381.